# US 2015/0175993 A1 · Novel synzymes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0175993 A1
- Document ID: US20150175993A1
- Status: Published application
- Kind: A1
- Application number: 14/406,999
- Filed: 2013-06-20
- Published: 2015-06-25
- Earliest claimed: 2012-06-20
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Michael J. Heller; Tsukasa Takahashi; Michelle Lillian Cheung
- Web page: https://patentgrep.com/patent/US20150175993A1

## CPC

- C12N 9/50: Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}
- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C12Y 304/22: Cysteine endopeptidases (3.4.22)
- G01N 2333/95: Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Novel synthetic catalytic structures or “synzymes,” e.g., synthetic polypeptides, with catalytic properties are provided. It is believed that these synthetic catalytic structures mimic some of the precise conformational changes necessary for catalytic activities seen in enzymes. The catalytic properties of these synthetic catalytic structures or synzymes can be further improved by the application of controlled external forces, e.g., electric fields.

## Claims

### Claim 1

A synthetic polypeptide comprising the amino acid sequence X1-X2-X3-X4-X5 (SEQ ID NO:1), wherein
X1, X3, and X5 are independently selected from the group consisting of alanine, an alanine analog, phenylalanine, and a phenylalanine analog;
X2 and X4 are independently selected from the group consisting of cysteine, a cysteine analog, serine, a serine analog, histidine, and a histidine analog;
wherein when X2 is histidine or a histidine analog, X4 is cysteine or a cysteine analog, or serine or a serine analog;
wherein when X4 is histidine or histidine analog, X2 is cysteine or cysteine analog, or serine or serine analog;
wherein the synthetic polypeptide is from 6 to 30 amino acids total in length;
wherein the alanine analog is selected from the group consisting of β-alanine, dehydroalanine, aminoisobutyric acid, valine and norvaline;
wherein the phenylalanine analog is selected from the group consisting of methylphenylalanine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, phenylglycine, ethyltyrosine, and methyltyrosine;
wherein the cysteine analog is selected from the group consisting of homocysteine and penicillamine;
wherein the serine analog is selected from the group consisting of methylserine, threonine, 2-amino-3-hydroxy-4-methylpentanoic acid, 3-amino-2-hydroxy-5-methylhexanoic acid, 4-amino-3-hydroxy-6-methylheptanoic acid, and 2-amino-3-hydroxy-3-methylbutanoic acid;
wherein the histidine analog is selected from the group consisting of β-(1,2,3-triazol-4-yl)-DL-alanine, and 1,2,4-triazole-3-alanine.

### Claim 2 (depends on 1)

The synthetic polypeptide of claim 1, wherein the synthetic polypeptide comprises a negatively charged C-terminal residue selected from the group consisting of aspartic acid, glutamic acid, methyl aspartic acid, methyl glutamic acid, 2-aminoadipic acid, 2-aminoheptanedioic acid, and iminodiacetic acid.

### Claim 3 (depends on 1)

The synthetic polypeptide of claim 1, wherein the synthetic polypeptide comprises an N-terminal residue selected from the group consisting of glycine, lysine, arginine, citrulline, ornithine, and 2-amino-3-guanidinopropionic acid.

### Claim 4 (depends on 1)

The synthetic polypeptide of claim 1, wherein the N-terminus of the synthetic polypeptide is protected and uncharged.

### Claim 5 (depends on 4)

The synthetic polypeptide of claim 4, wherein the N-terminus of the synthetic polypeptide is protected by a group selected from an acetyl, tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzoyloxycarbonyl, carbobenzyloxy, p-methoxybenzyl, p-methoxybenzyl carbonyl, benzoyl, benzyl, carbamate, p-methoxyphenyl, 3,4-dimethoxybenzyl, and tosyl group.

### Claim 6 (depends on 1)

The synthetic polypeptide of claim 1, wherein the C-terminus of the synthetic polypeptide is protected and uncharged.

### Claim 7 (depends on 6)

The synthetic polypeptide of claim 6, wherein the C-terminus of the synthetic polypeptide is protected by a group selected from a methyl, ethyl, benzyl, tert-butyl, silyl, and phenyl group.

### Claim 8

A synthetic polypeptide comprising an amino acid sequence selected from the group consisting of:
Ala-Cys-Ala-His-Ala (SEQ ID NO: 2);
Ala-Ser-Ala-His-Ala (SEQ ID NO: 3);
Phe-Cys-Phe-His-Ala (SEQ ID NO: 4);
Phe-Ser-Phe-His-Ala (SEQ ID NO: 5);
Phe-His-Phe-Cys-Ala (SEQ ID NO: 6);
Phe-His-Phe-Ser-Ala (SEQ ID NO: 7);
Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO: 8);
Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO: 9);
Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO: 10);
Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO: 11);
Asp-Phe-His-Phe-Cys-Ala (SEQ ID NO: 12);
Asp-Phe-His-Phe-Ser-Ala (SEQ ID NO: 13);
Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO: 14);
Ala-Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO: 15);
Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO: 16);
Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO: 17);
Asp-Phe-His-Phe-Cys-Ala-Gly (SEQ ID NO: 18);
Asp-Phe-His-Phe-Ser-Ala-Gly (SEQ ID NO: 19);
Gly-Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO: 20);
Gly-Ala-Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO: 21);
Gly-Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO: 22);
Gly-Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO: 23);
Asp-Phe-His-Phe-Cys-Ala-Gly-Asp (SEQ ID NO: 24);
Asp-Phe-His-Phe-Ser-Ala-Gly-Asp (SEQ ID NO: 25);
Gly-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO: 26);
Arg-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO: 27);
Arg-Gly-Ala-Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO: 28);
Arg-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO: 29);
Lys-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO: 30);
Arg-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO: 31);
Lys-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO: 32);
Arg-Asp-Phe-His-Phe-Cys-Ala-Gly-Asp (SEQ ID NO: 33);
Arg-Asp-Phe-His-Phe-Ser-Ala-Gly-Asp (SEQ ID NO: 34);
Arg-Gly-His-Gly-Gly-Pro-Gly-Gly-His-Gly-Cys-Gly-Asp (SEQ ID NO: 36); and
Arg-Gly-Gly-His-Phe-Cys-Gly-Pro-Gly-His-Gly-His-Gly-Asp (SEQ ID NO: 37), and
wherein the synthetic polypeptide is from 6 to 30 amino acids total in length.

### Claim 9 (depends on 8)

The synthetic polypeptide of claim 8, wherein the synthetic polypeptide comprises an amino acid sequence selected from the group consisting of:
Gly-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO: 26);
Arg-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO: 27);
Arg-Gly-Ala-Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO: 28);
Arg-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO: 29);
Lys-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO: 30);
Arg-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO: 31);
Lys-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO: 32);
Arg-Asp-Phe-His-Phe-Cys-Ala-Gly-Asp (SEQ ID NO: 33); and
Arg-Asp-Phe-His-Phe-Ser-Ala-Gly-Asp (SEQ ID NO: 34), and
wherein the synthetic polypeptide is from 9 to 15 amino acids total in length.

### Claim at position 10

-12. (canceled)

### Claim 13 (depends on 8)

The synthetic polypeptide of claim 8, wherein the synthetic polypeptide comprises the amino acid sequence Arg-Gly-His-Gly-Gly-Pro-Gly-Gly-His-Gly-Cys-Gly-Asp (SEQ ID NO: 36), and wherein the synthetic polypeptide is from 13 to 30 amino acids total in length.

### Claim 14 (depends on 8)

The synthetic polypeptide of claim 8, wherein the synthetic polypeptide comprises a negatively charged C-terminal residue selected from the group consisting of aspartic acid, glutamic acid, methyl aspartic acid, methyl glutamic acid, 2-aminoadipic acid, 2-aminoheptanedioic acid, and iminodiacetic acid.

### Claim 15 (depends on 8)

The synthetic polypeptide of claim 8, wherein the synthetic polypeptide comprises an N-terminal residue selected from the group consisting of glycine, lysine, arginine, citrulline, ornithine, and 2-amino-3-guanidinopropionic acid.

### Claim 16 (depends on 8)

The synthetic polypeptide of claim 8, wherein the N-terminus of the synthetic polypeptide is protected and uncharged.

### Claim 17 (depends on 16)

The synthetic polypeptide of claim 16, wherein the N-terminus of the synthetic polypeptide is protected by a group selected from an acetyl, tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzoyloxycarbonyl, carbobenzyloxy, p-methoxybenzyl, p-methoxybenzyl carbonyl, benzoyl, benzyl, carbamate, p-methoxyphenyl, 3,4-dimethoxybenzyl, and tosyl group.

### Claim 18 (depends on 8)

The synthetic polypeptide of claim 8, wherein the C-terminus of the synthetic polypeptide is protected and uncharged.

### Claim 19 (depends on 18)

The synthetic polypeptide of claim 18, wherein the C-terminus of the synthetic polypeptide is protected by a group selected from a methyl, ethyl, benzyl, tert-butyl, silyl, and phenyl group.

### Claim 20 (depends on 8)

The synthetic polypeptide of claim 8, wherein the synthetic polypeptide comprises the amino acid sequence Arg-Gly-Gly-His-Phe-Cys-Gly-Pro-Gly-His-Gly-His-Gly-Asp (SEQ ID NO: 37), and wherein the synthetic polypeptide is from 14 to 30 amino acids total in length.

### Claim at position 19

-26. (canceled)

### Claim 27 (depends on 8)

A synthetic polypeptide of claim 8, wherein the synthetic polypeptide is immobilized onto a solid surface.

### Claim 28 (depends on 27)

The synthetic polypeptide of claim 27, wherein the synthetic polypeptide is immobilized onto a solid surface through a charged group of the synthetic polypeptide, and wherein the charged group is selected from the group consisting of an α-amino group, an α-carboxyl group, an ε-amino group, and a sulfhydryl/thiol group.

### Claim 29 (depends on 28)

The synthetic polypeptide of claim 28, wherein the charged group is located on a terminal residue of the synthetic polypeptide.

### Claim 30 (depends on 28)

The synthetic polypeptide of claim 28, wherein the charged group is located on a residue within one to five amino acids from a terminus of the synthetic polypeptide.

### Claim 31 (depends on 28)

The synthetic polypeptide of claim 28, wherein the charged group is located on a linker conjugated to the synthetic polypeptide.

### Claim 32

An array of synthetic polypeptides comprising at least two synthetic polypeptides, wherein each synthetic polypeptide is from 9 to 15 amino acids total in length and comprises an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 2)
Ala-Cys-Ala-His-Ala;
(SEQ ID NO: 3)
Ala-Ser-Ala-His-Ala;
(SEQ ID NO: 4)
Phe-Cys-Phe-His-Ala;
(SEQ ID NO: 5)
Phe-Ser-Phe-His-Ala;
(SEQ ID NO: 6)
Phe-His-Phe-Cys-Ala;
(SEQ ID NO: 7)
Phe-His-Phe-Ser-Ala;
(SEQ ID NO: 8)
Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO: 9)
Ala-Ser-Ala-His-Ala-Asp;
(SEQ ID NO: 10)
Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO: 11)
Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO: 12)
Asp-Phe-His-Phe-Cys-Ala;
(SEQ ID NO: 13)
Asp-Phe-His-Phe-Ser-Ala;
(SEQ ID NO: 14)
Ala-Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO: 15)
Ala-Ala-Ser-Ala-His-Ala-Asp;
(SEQ ID NO: 16)
Ala-Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO: 17)
Ala-Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO: 18)
Asp-Phe-His-Phe-Cys-Ala-Gly;
(SEQ ID NO: 19)
Asp-Phe-His-Phe-Ser-Ala-Gly;
(SEQ ID NO: 20)
Gly-Ala-Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO: 21)
Gly-Ala-Ala-Ser-Ala-His-Ala-Asp;
(SEQ ID NO: 22)
Gly-Ala-Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO: 23)
Gly-Ala-Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO: 24)
Asp-Phe-His-Phe-Cys-Ala-Gly-Asp;
(SEQ ID NO: 25)
Asp-Phe-His-Phe-Ser-Ala-Gly-Asp;
(SEQ ID NO: 26)
Gly-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO: 27)
Arg-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO: 28)
Arg-Gly-Ala-Ala-Ser-Ala-His-Ala-Asp;
(SEQ ID NO: 29)
Arg-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO: 30)
Lys-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO: 31)
Arg-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO: 32)
Lys-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO: 33)
Arg-Asp-Phe-His-Phe-Cys-Ala-Gly-Asp;
(SEQ ID NO: 34)
Arg-Asp-Phe-His-Phe-Ser-Ala-Gly-Asp;
(SEQ ID NO: 36)
Arg-Gly-His-Gly-Gly-Pro-Gly-Gly-His-
Gly-Cys-Gly-Asp;
and
(SEQ ID NO: 37)
Arg-Gly-Gly-His-Phe-Cys-Gly-Pro-Gly-
His-Gly-His-Gly-Asp.

### Claim 33 (depends on 32)

The array of the synthetic polypeptides of claim 32, wherein the array of synthetic polypeptides comprises at least five synthetic polypeptides.

### Claim 34 (depends on 32)

The array of the synthetic polypeptides of claim 32, wherein the array of synthetic polypeptides comprises at least 15 synthetic polypeptides.

### Claim 35 (depends on 32)

The array of the synthetic polypeptides of claim 32, wherein the synthetic polypeptides are immobilized on a support or substrate.

### Claim 36 (depends on 8)

A kit comprising one or more synthetic polypeptides of claim 8.

### Claim 37 (depends on 36)

The kit of claim 36, wherein the kit further comprises one or more reaction wells.

### Claim 38 (depends on 37)

The kit of claim 37, wherein the one or more reaction wells are electric field cuvettes.

### Claim 39 (depends on 36)

The kit of claim 36, wherein the kit further comprises software configured to control application of electric fields to the one or more synthetic polypeptides of the kit.

### Claim 40 (depends on 8)

A method of hydrolyzing an amide or ester bond in a substrate comprising:
contacting an amide or ester bond containing substrate with one or more synthetic polypeptide of claim 8.

### Claim 41 (depends on 40)

The method of claim 40, wherein the amide or ester bond containing substrate is a peptide, protein, fatty acid, or glycerol ester.

### Claim 42 (depends on 40)

The method of claim 40, wherein step of contacting the amide or ester bond containing substrate is performed under conditions where a cysteine or cysteine analog, or a serine or serine analog of the synthetic polypeptide is nucleophilic,
wherein the cysteine analog is selected from the group consisting of homocysteine and penicillamine; and
wherein the serine analog is selected from the group consisting of methylserine, threonine, 2-amino-3-hydroxy-4-methylpentanoic acid, 3-amino-2-hydroxy-5-methylhexanoic acid, 4-amino-3-hydroxy-6-methylheptanoic acid, and 2-amino-3-hydroxy-3-methylbutanoic acid.

### Claim 43 (depends on 40)

The method of claim 40, wherein the step of contacting the amide or ester bond containing substrate is performed under conditions that allow formation of an acyl-sulfhydryl/thiol intermediate with the cysteine or cysteine analog, or an acyl-hydroxyl intermediate with the serine or serine analog, of the synthetic polypeptide.

### Claim 44 (depends on 40)

The method of claim 40, wherein the step of contacting the amide or ester bond containing substrate is performed under conditions that allow formation of an acyl-imidazole intermediate.

### Claim 45

(canceled)

### Claim 46 (depends on 40)

The method of claim 40, further comprising
applying an external electric field.

### Claim at position 40

-51. (canceled)

### Claim 52 (depends on 46)

The method of claim 46, wherein the external electrical field is applied in either one direction or in multiple directions.

### Claim 53 (depends on 46)

The method of claim 46, wherein the step of applying an external electric field comprises:
(i) applying a first directional electric field for less than one second to orient the synthetic polypeptide;
(ii) applying a second stronger directional electric field to facilitate formation of an acyl-imidazole intermediate; and
(iii) applying a third oscillating electric field to reduce the physical proximity of the acyl-imidazole intermediate and a nucleophilic sulfhydryl/thiol or hydroxyl group of the synthetic polypeptide.
